Abstract
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have